Alloy Therapeutics (Switzerland) AG (DeepCDR Biologics AG)

We harness the power of machine learning to move beyond experimental screening found in traditional therapeutic antibody discovery and engineering processes. To achieve this, we combine three state-of-the-art techniques in protein engineering: gene editing, deep sequencing, and deep learning. With our proprietary mammalian system and drug discovery workflow, we generate thousands of optimized lead candidates ready for preclinical studies at a fraction of the time and cost.